LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report
Scientific discussion

Folvidon
(folic acid)

Asp no: 2016-1770

This module reflects the scientific discussion for the approval of Folvidon. The procedure was finalised on 2017-10-10. For information on changes after this date please refer to the module 'Update'.

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se

I. INTRODUCTION

The application for Folvidon, 1 mg, tablet, is a line extension application (addition of new strength) made according to Article 10(1), generic application, of Directive 2001/83/EC. The applicant, Abigo Medical AB applies for a marketing authorisation in Sweden through a National Procedure. This PAR only concerns Folvidon, 1 mg, tablet, no PAR has been prepared for the previous approved Folvidon 5 mg, tablet.

The existing marketing authorisation in the member state where the application is made is Folvidon 5 mg, tablet.

The reference medicinal product chosen for the purposes of establishing the expiry of the data protection period is Folacin, 5 mg, tablet, authorised in Sweden since 1950, with Pfizer as marketing authorisation holder. No bioequivalence studies have been conducted.

For approved indications, see the Summary of Product Characteristics.

For recommendations to the marketing authorisation not falling under Article 21a/22 of Directive 2001/83 and conditions to the marketing authorisation pursuant to Article 21a or 22 of Directive 2001/83/EC to the marketing authorisation, please see section VI.

II. QUALITY ASPECTS

II.1 Drug Substance

The structure of the drug substance has been adequately proven and its physico-chemical properties are sufficiently described.

The manufacture of the drug substance has been adequately described and satisfactory specifications have been provided for starting materials, reagents and solvents.

The drug substance specification includes relevant tests and the limits for impurities and degradation products have been justified. The analytical methods applied are suitably described and validated.

Stability studies confirm the retest period.

II.2 Medicinal Product

The medicinal product is formulated using excipients listed in section 6.1 in the Summary of Product Characteristics.

The manufacturing process has been sufficiently described and critical steps identified.

The tests and limits in the specification are considered appropriate to control the quality of the finished product in relation to its intended purpose.

Stability studies have been performed and data presented support the shelf life and special precautions for storage claimed in the Summary of Product Characteristics, sections 6.3 and 6.4.

III. NON-CLINICAL ASPECTS

III.1 Discussion on the non-clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to preclinical data, no further such data have been submitted or are considered necessary.

IV. CLINICAL ASPECTS

IV.1 Pharmacokinetics

No new data has been provided for this line extension. A biowaiver for this additional strength can be accepted based on quality data.

IV.2 Discussion on the clinical aspects

Since this product has been shown to be essentially similar and refer to a product approved based on a full application with regard to clinical efficacy/safety data, no further such data have been submitted or are considered necessary.

IV.3 Risk Management Plan

The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Folvidon.

Safety specification

Summary table of safety concerns as approved in RMP

Important identified risks	Masking of B12 deficiency Stimulation of cell division in folate dependent tumours.
Important potential risks	None currently identified
Missing information	None currently identified

Pharmacovigilance Plan

Routine pharmacovigilance is suggested and no additional pharmacovigilance activities are proposed by the applicant, which is endorsed.

Risk minimisation measures

Routine risk minimisation is suggested and no additional risk minimisation activities are proposed by the applicant, which is endorsed.

Summary of Safety Concerns and Planned Risk Minimisation Activities as proposed/ approved in RMP

Safety Concern	Routine Risk Minimisation Measures	Additional Risk Minimisation Measures
Important Identified Risks		
Masking of B12 deficiency	The SmPC for Folvidon includes a wording in section 4.4 that there is a risk that a B12 deficiency can be masked.	Non applicable
Stimulation of cell division in folate dependent tumours.	The SmPC for Folvidon includes a wording in section 4.4 that folate may increase cell division and that patients with folate dependent tumours should be treated with caution.	Non applicable
Important Potential Risks		
Non applicable		
Missing Information		
Non applicable		

Summary of the RMP
The RMP is approved.
The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.
An updated RMP should be submitted:

- At the request of the RMS;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time, but via different procedures.

V. USER CONSULTATION

A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to Folvidon 5 mg, national procedure 111:2006/68873. The bridging report submitted by the applicant has been found acceptable.

VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION

The quality of the product, Folvidon, is found adequate. There are no objections to approval of Folvidon, from a non-clinical and clinical point of view.

The product information is acceptable. The application is therefore recommended for approval.

List of recommendations not falling under Article 21a/22 of Directive 2001/83 in case of a positive benefit risk assessment

N/A

List of conditions pursuant to Article 21a or 22 of Directive 2001/83/EC

N/A

VII. APPROVAL

Folvidon, 1 mg, tablet was approved in the national procedure on 2017-10-10.

LÄKEMEDELSVERKET
MEDICAL PRODUCTS AGENCY

Public Assessment Report – Update

Procedure number*	Scope	Product Information affected	Date of end of procedure	Approval/ non approval	Summary/ Justification for refuse

*Only procedure qualifier, chronological number and grouping qualifier (when applicable)

Postadress/Postal address: P.O. Box 26, SE-751 03 Uppsala, SWEDEN
Besöksadress/Visiting address: Dag Hammarskjölds väg 42, Uppsala
Telefon/Phone: +46 (0)18 17 46 00 Fax: +46 (0)18 54 85 66
Internet: www.mpa.se E-mail: registrator@mpa.se